Z.C. and R.T. contributed equally to this work.
Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes†
Article first published online: 21 JUL 2009
Copyright © 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 48, Issue 35, pages 6494–6498, August 17, 2009
How to Cite
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, Gerard C. L., Cheng, J. and Lu, Y. (2009), Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes. Angew. Chem. Int. Ed., 48: 6494–6498. doi: 10.1002/anie.200901452
This work was supported by a National Science Foundation Nanoscale Science and Engineering Center grant (DMR-0117792). J.C. thanks support from the National Science Foundation Career Program (DMR-0748834) and the Siteman Center for Cancer Nanotechnology Excellence (SCCNE, Washington University)—Center for Nanoscale Science and Technology (CNST, UIUC).
- Issue published online: 12 AUG 2009
- Article first published online: 21 JUL 2009
- Manuscript Revised: 6 JUN 2009
- Manuscript Received: 17 MAR 2009
- National Science Foundation Nanoscale Science and Engineering Center. Grant Number: DMR-0117792
- National Science Foundation Career Program. Grant Number: DMR-0748834
- Siteman Center for Cancer Nanotechnology Excellence (SCCNE, Washington University)—Center for Nanoscale Science and Technology (CNST, UIUC)
- drug delivery;
Aptamer advantages: Cell-specific delivery of the anticancer drug cisplatin through a nucleolin-aptamer-conjugated, cisplatin-encapsulating liposome delivery system is described. Calcein was incorporated into the target MCF-7 cells (see top image) but not into LNCaP cells (see bottom image). More importantly, the extent of delivery can be controlled by using a complementary DNA of the aptamer as an antidote.